There might not be a better place to find winning stocks that can slowly make you wealthy over decades than the healthcare ...
Johnson & Johnson stock (NYSE: JNJ) lost about 7% in 2024, underperforming the broader S&P 500 index, which gained 23% for ...
Graypoint LLC lessened its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 7.1% during the 4th quarter, according ...
This was the stock's fourth consecutive day of losses.
AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...
In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...
AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...